Dexrazoxane
From Wikipedia, the free encyclopedia
 |
|
|
Dexrazoxane
|
|
| Systematic (IUPAC) name | |
| 4-[1-(3,5-dioxopiperazin-1-yl) propan-2-yl]piperazine-2,6-dione | |
| Identifiers | |
| CAS number | |
| ATC code | V03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H16N4O4 |
| Mol. mass | 268.269 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Dexrazoxane hydrochloride (Zinecard [Pfizer for USA & Canada]; Cardioxane [Novartis for EU & ROW]) is a medication used to protect the heart against the cardiotoxic side effects of anthracycline chemotherapy. As a derivative of EDTA, dexrazoxane chelates iron, but the precise mechanism by which it protects the heart is not known.
FDA has also approved a dexrazoxane hydrochloride drug, brand name Totect, for use as a treatment of extravasation resulting from IV anthracycline chemotherapy.[1] Extravasation is an adverse event in which chemotherapies containing anthracylines leak out of the blood vessel and necrotize the surrounding tissue.
[edit] References
|
|||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
